Eagle Pharmaceuticals jumps after Q3 results beat

Eagle Pharmaceuticals

07/11/2022 15:33

** Pharma firm Eagle Pharmaceuticals Inc's shares  EGRX.O 
jump 19% at $37.47 
    ** EGRX posts Q3 earnings and revenue ahead of analysts'
estimates - Refinitiv IBES data
    ** Scott Tarriff, president and chief executive of EGRX,
sees 2023 to be another strong year and expects "to potentially
make an accretive acquisition to round out our portfolio" 
    ** One of three brokerages rate the stock "buy" or higher,
two "hold"; their median PT is $43
    ** Stock had fallen 26% YTD vs a 36% decline in the S&P 600
Biotechnology industry index  .SPSMCBIOT 
 (Reporting by Johann M Cherian in Bengaluru)
 ((johann.mcherian@thomsonreuters.com;))